Dr. Reddy's Fell 6% Today — Here's What Actually Happened

dropped as much as 6.5% today after the company informed stock exchanges that certain batches of its semaglutide (weight-loss drug) were found "out of specification" due to an issue with the active pharmaceutical ingredient. As a result, the company is voluntarily delaying commercial supply while it investigates. A few things worth understanding here, beyond the headline drop. First, the company has clarified there's no patient safety impact and no effect on its existing global regulatory filings — this is a manufacturing/quality-control issue, not a product recall or safety scandal. That distinction matters: markets often react hardest to uncertainty, and a company proactively pausing supply to investigate is different from being forced to by a regulator. Second, the timing adds context. Semaglutide (Dr. Reddy's brand: Obeda) was one of the company's most closely watched growth bets, in a fast-growing weight-loss and diabetes drug category where several Indian pharma companies are racing for market share after patent expiries. A delay here doesn't kill that opportunity, but it does mean competitors get a bit more runway to capture share while Dr. Reddy's supply is paused. The broader lesson: single-product news, even from one drug out of a company's full portfolio, can move the stock disproportionately when that product was a significant part of the growth story investors were pricing in. It's a reminder to look at how concentrated a company's near-term growth narrative is on any one product or segment before reacting to news about it.